Ionizable Lipid LNP Formulation for Stable mRNA Transfection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing nucleic acid delivery systems, particularly lipid nanoparticles, face challenges in efficiently and stably delivering mRNA and siRNA to target sites within cells.
Innovation Solution
A novel ionizable lipid compound with specific structural features, including variations in L1 and L2 linkages and R1 and R2 groups, is used to formulate lipid nanoparticles that enhance delivery efficiency and stability, particularly when combined with polyethylene glycol, steroid, and neutral lipids.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cationic lipid compounds are used for nucleic acid delivery, then electrostatic interaction with endosomal membrane occurs, but transfection efficiency and delivery stability remain insufficient
Solution Approach 1:
The patent modifies the chemical structure of cationic lipids by varying the hydrophobic chain length (C16-C24), linker types (amide, carbamate, carbonate, urea), and headgroup compositions to optimize both transfection efficiency and delivery stability. Specific structural parameters are adjusted to achieve balanced performance in cellular uptake and endosomal escape
Solution Approach 2:
The invention combines cationic lipids with other lipid components (neutral lipids, PEG-lipids, cholesterol) to form composite lipid formulations. This composite approach synergistically improves delivery stability through enhanced structural integrity while maintaining high transfection efficiency via optimized surface properties and cellular interaction
2Quantity of substance
If lipid nanoparticle formulations are used for mRNA and siRNA delivery, then nucleic acid encapsulation is achieved, but efficient delivery to target sites within cells is challenging
Solution Approach 1:
The patent designs lipid molecules with differentiated functional regions: hydrophobic tails for membrane integration, ionizable headgroups for pH-responsive endosomal escape, and optimized charge density for nucleic acid binding. This local functional differentiation enables simultaneous achievement of stable encapsulation and efficient intracellular delivery
Solution Approach 2:
The invention utilizes pH-responsive ionizable lipids that dynamically change their charge state in response to environmental pH. The lipids remain neutral at physiological pH for stable encapsulation but become positively charged in the acidic endosomal environment to facilitate membrane disruption and nucleic acid release, thereby improving delivery efficiency
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel lipid compound improves the stability and transfection efficiency of nucleic acid delivery, leading to a higher specific antibody response in experimental animals and effective delivery of mRNA vaccines.
Implementation Method 1
A cationic liposome is positively charged, and has electrostatic interaction with a negatively-charged membrane lipid in an endosome
Implementation Method 2
LNPs are generally prepared from four types of lipids in a certain proportion... for delivering a bioactive substance into a body
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
Provided are an ionizable lipid compound of formula I for nucleic acid delivery and an LNP composition thereof, which can efficiently and stably deliver a biologically active substance to a target cell or an organ. The mRNA LNP prepared by using the lipid compound as a cationic lipid has better stability and transfection efficiency, and can cause a higher specific antibody response in an experimental animal body.